Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Raw Materials (2022 - 2025)

Historic Raw Materials for Envoy Medical (COCH) over the last 4 years, with Q3 2025 value amounting to $1.4 million.

  • Envoy Medical's Raw Materials rose 117.82% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 117.82%. This contributed to the annual value of $1.4 million for FY2024, which is 1927.71% up from last year.
  • Latest data reveals that Envoy Medical reported Raw Materials of $1.4 million as of Q3 2025, which was up 117.82% from $1.4 million recorded in Q2 2025.
  • Envoy Medical's Raw Materials' 5-year high stood at $1.4 million during Q1 2025, with a 5-year trough of $1.0 million in Q4 2022.
  • In the last 4 years, Envoy Medical's Raw Materials had a median value of $1.4 million in 2024 and averaged $1.3 million.
  • In the last 5 years, Envoy Medical's Raw Materials surged by 1927.71% in 2024 and then soared by 115.11% in 2025.
  • Over the past 4 years, Envoy Medical's Raw Materials (Quarter) stood at $1.0 million in 2022, then increased by 15.05% to $1.2 million in 2023, then grew by 19.28% to $1.4 million in 2024, then dropped by 0.87% to $1.4 million in 2025.
  • Its Raw Materials was $1.4 million in Q3 2025, compared to $1.4 million in Q2 2025 and $1.4 million in Q1 2025.